India Globalization Capital, Inc.(NYSE Amex Equities : IGC)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -0.21% | 184.44 | 1.3% | $519.00m | |
| CELG | Celgene Corporation | -0.30% | 93.19 | 1.3% | $445.71m | |
| ARRY | Array BioPharma Inc. | -0.04% | 46.21 | 8.1% | $438.16m | |
| GILD | Gilead Sciences, Inc. | -0.52% | 68.48 | 0.9% | $400.25m | |
| BIIB | Biogen Inc. | 1.86% | 240.29 | 1.3% | $378.55m | |
| ILMN | Illumina, Inc. | 0.10% | 358.08 | 3.5% | $306.42m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.11% | 312.90 | 2.6% | $247.20m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.48% | 180.15 | 1.9% | $217.00m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.44% | 125.15 | 2.0% | $206.29m | |
| EXAS | Exact Sciences Corporation | -2.04% | 111.45 | 24.1% | $189.07m | |
| A | Agilent Technologies, Inc. | -0.90% | 72.48 | 1.6% | $157.16m | |
| BMRN | BioMarin Pharmaceutical Inc. | -2.42% | 83.82 | 4.3% | $127.70m | |
| INCY | Incyte Corporation | 0.79% | 87.61 | 2.5% | $115.84m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.50% | 124.16 | 14.7% | $113.30m | |
| MRTX | Mirati Therapeutics Inc. | 1.38% | 102.14 | 2.5% | $107.52m |
Company Profile
India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications such as Alzheimer's disease, Parkinson's disease, and pain. It operates through the Infrastructure Business and Plant & Cannabinoids Business segments. The Infrastructure Business segment involves the rental of heavy construction equipment, execution of construction contracts, and purchase and reseal of physical commodities used in infrastructure. The Plant & Cannabinoids Business segment comprises the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.